BCAA metabolic reprogramming identifies BCKDK as a therapeutic target in cancer

Expert Opinion on Therapeutic Targets · Published 2026-07-24 · DOI 10.1080/14728222.2026.2709804

Authors (4)

Zhihan Li, Yuxuan Zhou, Li Zhang, Quanjun Yang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Li, Z., Zhou, Y., Zhang, L., et al. (2026). BCAA metabolic reprogramming identifies BCKDK as a therapeutic target in cancer. Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2026.2709804

Related articles

• Advancements in the molecular understanding of major depressive disorder uncovering novel targets with therapeutic promise: focus on recurrence of illness · Expert Opinion on Therapeutic Targets · 2025 · Same journal
• Modulating tonic NMDA receptor currents: mechanistic insights into ketamine, esketamine, and dextromethorphan for major depressive disorder and implications for the discovery and development of investigational agents · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• Molecular targets in gastric cancer for nanomedicine therapeutics: mechanistic insights and translational progress · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• AQP7 suppresses cell stemness and metastasis by targeting Wnt signaling in basal-like breast cancer · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• CDK7 as a New therapeutic target in pancreatic and lung cancer: current evidence and future perspectives · Expert Opinion on Therapeutic Targets · 2025 · Same journal
• Advances in CGRP therapeutic targets for migraine: where do we stand 5 years later? · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• Transient receptor potential (TRP) channels: an emerging therapeutic target for the treatment of cardiac hypertrophy · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• Lipopolysaccharide-targeting treatments for multidrug-resistant Pseudomonas aeruginosa · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• 5-FU in combination with PARP inhibitor ABT-888 deregulates MGMT-dependent mismatch repair (MMR) pathway in MMR-proficient colorectal cancer stem cells by modulating MGMT/PARP1/MSH6 complex · Expert Opinion on Therapeutic Targets · 2026 · Same journal
• Unveiling the role of mineralocorticoid receptor antagonists in epilepsy: the intersection of seizures, stress, and neuroinflammation · Expert Opinion on Therapeutic Targets · 2025 · Same journal